Steinhart Richard I — SEC insider filings
SEC reporting owner CIK 1293789. 39 insider filings on record with FilingPulse; latest filed 2026-09-04.
Transaction summary — filings shown
Covers all 39 filings on record, filed 2020-08-14 to 2026-09-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 9 filings — 27,228 shares, $372,176 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 89.
- Largest priced transaction: sale of 3,750 shares @ $48.15 ($180,562) in BioXcel Therapeutics, Inc., filed 2021-02-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | 27 | — | 10 legs · 27,228 sh · $372,176 | 69 |
| Actinium Pharmaceuticals, Inc. (ATNM) | Director | 6 | — | — | 14 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | Director | 6 | — | — | 6 |
Insider filings — Steinhart Richard I
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-04 | 4 | Actinium Pharmaceuticals, Inc. (ATNM) | Grant/award (A): 62,800 @ $0 · Grant/award (A): 94,200 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 35 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 17,500 · Sale (S): 6,845 @ $1.08 · Option exercise (M): 17,500 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | ATOSSA THERAPEUTICS, INC. (ATOS) | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-05-07 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 9,000 · Option exercise (M): 9,000 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-07-22 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 4,375 · Option exercise (M): 625 · Option exercise (M): 625 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | ATOSSA THERAPEUTICS, INC. (ATOS) | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Actinium Pharmaceuticals, Inc. (ATNM) | Disposition to issuer (D): 2,500 (derivative) @ $0 · Disposition to issuer (D): 2,500 (derivative) @ $0 · Disposition to issuer (D): 2,500 (derivative) @ $0 · Disposition to issuer (D): 8,333 (derivative) @ $0 · Disposition to issuer (D): 8,333 (derivative) @ $0 · Disposition to issuer (D): 18,351 (derivative) @ $0 · +2 more | EDGAR |
| 2025-04-01 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 625 (derivative) @ $0 · Grant/award (A): 1,875 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 31 · Option exercise (M): 34 · Option exercise (M): 31 (derivative) @ $0 · Option exercise (M): 34 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 270,000 (derivative) @ $0 | EDGAR |
| 2024-12-17 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 521 · Option exercise (M): 562 · Sale (S): 205 @ $0.36 · Sale (S): 372 @ $0.36 · Option exercise (M): 521 (derivative) @ $0 · Option exercise (M): 562 (derivative) @ $0 | EDGAR |
| 2024-10-03 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 21,250 · Sale (S): 7,175 @ $0.55 | EDGAR |
| 2024-09-17 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 521 · Option exercise (M): 563 · Sale (S): 356 @ $0.69 · Option exercise (M): 521 (derivative) @ $0 · Option exercise (M): 563 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | ATOSSA THERAPEUTICS, INC. (ATOS) | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 521 · Option exercise (M): 562 · Sale (S): 372 @ $1.26 · Option exercise (M): 521 (derivative) @ $0 · Option exercise (M): 562 (derivative) @ $0 | EDGAR |
| 2024-04-08 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 521 · Option exercise (M): 2,250 · Sale (S): 1,069 @ $2.63 · Option exercise (M): 521 (derivative) @ $0 · Option exercise (M): 2,250 (derivative) @ $0 | EDGAR |
| 2023-12-29 | 4 | Actinium Pharmaceuticals, Inc. (ATNM) | Grant/award (A): 70,311 (derivative) @ $0 | EDGAR |
| 2023-12-18 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 521 · Option exercise (M): 521 (derivative) @ $0 | EDGAR |
| 2023-09-18 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 521 · Option exercise (M): 521 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 521 · Option exercise (M): 521 (derivative) @ $0 | EDGAR |
| 2023-05-16 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 5,000 · Sale (S): 5,000 @ $27.17 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2023-05-05 | 4 | ATOSSA THERAPEUTICS, INC. (ATOS) | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2023-03-16 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 2,084 · Sale (S): 2,084 @ $19.50 · Option exercise (M): 2,084 (derivative) @ $0 · Grant/award (A): 9,000 (derivative) @ $0 · Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2022-07-01 | 4 | Actinium Pharmaceuticals, Inc. (ATNM) | Grant/award (A): 72,156 (derivative) @ $0 | EDGAR |
| 2022-05-17 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2022-05-16 | 4 | ATOSSA THERAPEUTICS, INC. (ATOS) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-03-16 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 8,337 (derivative) @ $0 · Grant/award (A): 33,350 (derivative) @ $0 | EDGAR |
| 2021-09-03 | 4 | Actinium Pharmaceuticals, Inc. (ATNM) | Grant/award (A): 18,351 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | ATOSSA THERAPEUTICS, INC. (ATOS) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2021-03-29 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 3,750 @ $5.55 · Sale (S): 3,750 @ $48.15 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2020-08-14 | 4 | Actinium Pharmaceuticals, Inc. (ATNM) | Grant/award (A): 8,333 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1293789 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs